SCM
AKRO

Sio Capital Management’s Akero Therapeutics AKRO Stock Holding History

Sio Capital Management’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-85,000
Closed -$3.44M – 53
2025
Q1 		$3.44M Buy
+85,000
New +$3.6M 1.02% 25

Other funds holding AKRO

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GA
General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sio Capital Management's AKRO Position: Q2 2025 in Review

Sio Capital Management sold out of Akero Therapeutics (AKRO) in Q2 2025, closing a stake of 85,000 shares — an estimated $3.44M sold.

Sio Capital Management first reported a position in AKRO in Q1 2025 and held it in 1 quarter. The position peaked at $3.44M in Q1 2025. 257 funds tracked by Wall St. Rank hold AKRO as of Q2 2025.

  • Sio Capital Management reported no remaining Akero Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Sio Capital Management sold 85,000 Akero Therapeutics shares in Q2 2025, an estimated $3.44M.
  • Sio Capital Management first reported a position in Akero Therapeutics in Q1 2025 and held it in 1 quarter.
  • Sio Capital Management's Akero Therapeutics position peaked at $3.44M in Q1 2025.
  • 257 funds tracked by Wall St. Rank held Akero Therapeutics as of Q2 2025.

Based on Sio Capital Management's 13F filing for Q2 2025, filed 13 Aug 2025.